In this interview, Donna Catamero, NP, Associate Director at the Tish Cancer Institute, Mount Sinai, discusses the complexities of diagnosing and treating multiple myeloma, the second most common hematological malignancy. Donna highlights the importance of early detection, typical presentation, populations at higher risk, and disparities in treatment among different demographic groups. She also notes the significant advancements in therapy that have improved patient outcomes over the years.
Key discussion points:
Sign up below to get lorem ipsum dolor sit amet inos a consecte tura adipiscing elit proinas inosam.
Sign up to receive the latest expert articles, event updates, and educational resources to stay informed about multiple myeloma and protein diagnostics.
Choose your Region
Region
By selecting a different country/region, you are choosing to view another site. Product availability and indiciation may vary from what is provided in your region.
You are about to visit an alternative version of our website. Please be aware that the products and claims presented there may not have been reviewed or cleared by your local regulatory body. Additionally, the language and settings may vary. By proceeding, you acknowledge that you understand these conditions and accept any risks associated with visiting the alternative website.
